These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 9830012)

  • 21. Conformational exchange in the potassium channel blocker ShK.
    Iwakawa N; Baxter NJ; Wai DCC; Fowler NJ; Morales RAV; Sugase K; Norton RS; Williamson MP
    Sci Rep; 2019 Dec; 9(1):19307. PubMed ID: 31848433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction of the Inhibitory Peptides ShK and HmK with the Voltage-Gated Potassium Channel K
    Sanches K; Prypoten V; Chandy KG; Chalmers DK; Norton RS
    J Chem Inf Model; 2023 May; 63(10):3043-3053. PubMed ID: 37143234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-guided transformation of charybdotoxin yields an analog that selectively targets Ca(2+)-activated over voltage-gated K(+) channels.
    Rauer H; Lanigan MD; Pennington MW; Aiyar J; Ghanshani S; Cahalan MD; Norton RS; Chandy KG
    J Biol Chem; 2000 Jan; 275(2):1201-8. PubMed ID: 10625664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure of the voltage-gated potassium channel K
    Chandy KG; Sanches K; Norton RS
    Channels (Austin); 2023 Dec; 17(1):2253104. PubMed ID: 37695839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.
    Beeton C; Pennington MW; Norton RS
    Inflamm Allergy Drug Targets; 2011 Oct; 10(5):313-21. PubMed ID: 21824083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation.
    Rashid MH; Heinzelmann G; Huq R; Tajhya RB; Chang SC; Chhabra S; Pennington MW; Beeton C; Norton RS; Kuyucak S
    PLoS One; 2013; 8(11):e78712. PubMed ID: 24244345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Affinity and selectivity of ShK toxin for the Kv1 potassium channels from free energy simulations.
    Rashid MH; Kuyucak S
    J Phys Chem B; 2012 Apr; 116(16):4812-22. PubMed ID: 22480371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone.
    Pennington MW; Byrnes ME; Zaydenberg I; Khaytin I; de Chastonay J; Krafte DS; Hill R; Mahnir VM; Volberg WA; Gorczyca W
    Int J Pept Protein Res; 1995 Nov; 46(5):354-8. PubMed ID: 8567178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3.
    Murray JK; Qian YX; Liu B; Elliott R; Aral J; Park C; Zhang X; Stenkilsson M; Salyers K; Rose M; Li H; Yu S; Andrews KL; Colombero A; Werner J; Gaida K; Sickmier EA; Miu P; Itano A; McGivern J; Gegg CV; Sullivan JK; Miranda LP
    J Med Chem; 2015 Sep; 58(17):6784-802. PubMed ID: 26288216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoxia modulates early events in T cell receptor-mediated activation in human T lymphocytes via Kv1.3 channels.
    Robbins JR; Lee SM; Filipovich AH; Szigligeti P; Neumeier L; Petrovic M; Conforti L
    J Physiol; 2005 Apr; 564(Pt 1):131-43. PubMed ID: 15677684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation.
    Beeton C; Barbaria J; Giraud P; Devaux J; Benoliel AM; Gola M; Sabatier JM; Bernard D; Crest M; Béraud E
    J Immunol; 2001 Jan; 166(2):936-44. PubMed ID: 11145670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity.
    Baell JB; Gable RW; Harvey AJ; Toovey N; Herzog T; Hänsel W; Wulff H
    J Med Chem; 2004 Apr; 47(9):2326-36. PubMed ID: 15084131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ionisation behaviour and solution properties of the potassium-channel blocker ShK toxin.
    Tudor JE; Pennington MW; Norton RS
    Eur J Biochem; 1998 Jan; 251(1-2):133-41. PubMed ID: 9492277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The 'functional' dyad of scorpion toxin Pi1 is not itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels.
    Mouhat S; Mosbah A; Visan V; Wulff H; Delepierre M; Darbon H; Grissmer S; De Waard M; Sabatier JM
    Biochem J; 2004 Jan; 377(Pt 1):25-36. PubMed ID: 12962541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A three-residue, continuous binding epitope peptidomimetic of ShK toxin as a Kv1.3 inhibitor.
    Harvey AJ; Gable RW; Baell JB
    Bioorg Med Chem Lett; 2005 Jul; 15(13):3193-6. PubMed ID: 15935664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brownian dynamics simulations of the recognition of the scorpion toxin maurotoxin with the voltage-gated potassium ion channels.
    Fu W; Cui M; Briggs JM; Huang X; Xiong B; Zhang Y; Luo X; Shen J; Ji R; Jiang H; Chen K
    Biophys J; 2002 Nov; 83(5):2370-85. PubMed ID: 12414674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels.
    Koo GC; Blake JT; Shah K; Staruch MJ; Dumont F; Wunderler D; Sanchez M; McManus OB; Sirotina-Meisher A; Fischer P; Boltz RC; Goetz MA; Baker R; Bao J; Kayser F; Rupprecht KM; Parsons WH; Tong XC; Ita IE; Pivnichny J; Vincent S; Cunningham P; Hora D; Feeney W; Kaczorowski G
    Cell Immunol; 1999 Nov; 197(2):99-107. PubMed ID: 10607427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
    Tarcha EJ; Chi V; Muñoz-Elías EJ; Bailey D; Londono LM; Upadhyay SK; Norton K; Banks A; Tjong I; Nguyen H; Hu X; Ruppert GW; Boley SE; Slauter R; Sams J; Knapp B; Kentala D; Hansen Z; Pennington MW; Beeton C; Chandy KG; Iadonato SP
    J Pharmacol Exp Ther; 2012 Sep; 342(3):642-53. PubMed ID: 22637724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure, folding and stability of a minimal homologue from Anemonia sulcata of the sea anemone potassium channel blocker ShK.
    Krishnarjuna B; MacRaild CA; Sunanda P; Morales RAV; Peigneur S; Macrander J; Yu HH; Daly M; Raghothama S; Dhawan V; Chauhan S; Tytgat J; Pennington MW; Norton RS
    Peptides; 2018 Jan; 99():169-178. PubMed ID: 28993277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties.
    Schmalhofer WA; Bao J; McManus OB; Green B; Matyskiela M; Wunderler D; Bugianesi RM; Felix JP; Hanner M; Linde-Arias AR; Ponte CG; Velasco L; Koo G; Staruch MJ; Miao S; Parsons WH; Rupprecht K; Slaughter RS; Kaczorowski GJ; Garcia ML
    Biochemistry; 2002 Jun; 41(24):7781-94. PubMed ID: 12056910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.